Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ACB vs IONX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ACB Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 9–1 Matrix Metrics)

ACB Overall Winner 6-Pillar Tally: ACB 6 – 0 IONX Matrix Metrics: ACB 9 – 1 IONX

As of Nov 16, 2026, Aurora Cannabis Inc. Common Shares (ACB) is the stronger overall head-to-head candidate over Defiance Daily Target 2X Long IONQ ETF (IONX) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ACB carries a Unified Composite Score of 40.1/100 (SELL) at $4.61 (109.9x Forward P/E, -13.8% operating margin), whereas IONX carries 48.8/100 (HOLD) at $8.27 (N/M Forward P/E, N/A operating margin).

  • Composite vs. Pillar Nuance: While IONX currently prints a higher short-term Unified Composite Score (48.8/100 HOLD vs. ACB 40.1/100 SELL), ACB captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (-13.8% vs. N/A operating margin) and revenue trajectory (-8.8% vs. N/A YoY).
  • Technical & Structure Timing Caution: ACB trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.1); meanwhile IONX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ACB vs IONX
ACB NASDAQ Head-to-Head Winner
Aurora Cannabis Inc. Common Shares
Medicinal Chemicals & Botanical Products
$4.61
-6.68% 1D
Market Cap $324.8M
TTM Revenue $314M
Forward P/E 109.9x
Beta / 30D Vol 1.07β · 87% Vol
Unified Composite Score
40.1 / 100 SELL
Tech 15.0 Fund 40.0 Flow 61.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (7.2% over 20 days), RSI 51
RSI-14: 51.1 · SMA20: $4.55 · SMA50: $4.27
IONX NASDAQ
Defiance Daily Target 2X Long IONQ ETF
Institutional Equity
$8.27
-16.55% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 6.79β · 232% Vol
Unified Composite Score
48.8 / 100 HOLD
Tech 45.0 Fund 51.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -24.5%), weak momentum, RSI 35
RSI-14: 35.0 · SMA20: $12.36 · SMA50: $18.40

6-Pillar Scorecard Institutional Category Breakdown (ACB 6 – 0 IONX)

Columns: Metric · ACB · IONX
1. Valuation Multiples ACB
Forward P/E 109.9x N/M
Trailing P/E 109.9x N/M
PEG Ratio N/M N/M
EV / Revenue 0.9x N/M
2. Growth & Scale ACB
Revenue Growth (YoY) -8.8% N/A
Earnings Growth (YoY) -94.7% N/A
TTM Revenue (USD) $314M N/A
Market Cap $324.8M N/A
3. Profitability & Quality ACB
Gross Margin 44.2% N/A
Operating Margin -13.8% N/A
Net Profit Margin -38.2% N/A
Return on Equity (ROE) -9.4% N/A
4. Balance Sheet & Cash Flow ACB
Cash Generation (TTM) -$25M N/A
Cash Flow Margin -8.1% N/A
Net Cash / Leverage $44M Net Cash N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ACB
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 30.2% (6th %ile) 181.8% (4th %ile)
Put/Call OI Skew 0.18x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat ACB
OpEx & R&D Intensity 58.0% of Rev ($182M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ACB (9) vs IONX (1)
Institutional Metric ACB IONX Criterion Row Edge
Market Capitalization
Scale
$324.8M N/A Larger Scale ACB
Trailing P/E Ratio
Valuation
109.9x N/M Lower Multiple ACB
Forward P/E Ratio
Valuation
109.9x N/M Lower Multiple ACB
Revenue Growth (YoY)
Growth
-8.8% N/A Higher Growth ACB
Operating Margin (TTM)
Profitability
-13.8% N/A Higher Margin ACB
Net Profit Margin
Profitability
-38.2% N/A Higher Margin ACB
Return on Equity (ROE)
Capital Efficiency
-9.4% N/A Higher ROE ACB
52-Week Range Position
Momentum
54% ($3–$6) 0% ($8–$108) Stronger Trend ACB
Beta / 30D Volatility
Risk Regime
1.07β · 87% Vol 6.79β · 232% Vol Lower Realized Risk ACB
Unified Institutional Score
Composite Signal
40.1 / 100 (SELL) 48.8 / 100 (HOLD) Higher Composite IONX
Trailing 12M Revenue (USD)
Operating Scale
$314M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
44.2% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.9x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$25M ($44M Net Cash) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ACB +52.36 pp
ACB: +15.54% · IONX: -36.82%
3M Horizon ACB +98.33 pp
ACB: +25.61% · IONX: -72.72%
6M Horizon ACB +124.3 pp
ACB: +40.55% · IONX: -83.75%
1Y Horizon ACB +89.52 pp
ACB: +5.01% · IONX: -84.51%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ACB vs IONX. Trailing 12-month operating profitability (ACB -13.8% vs IONX N/A) and valuation multiples (ACB 109.9x vs IONX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ACB ADR TTM Benchmark FX-Normalized USD
TTM Revenue$314M
Gross Margin44.2%
Op. Margin-13.8%
ROE / Fwd P/E-9.4% · 109.9x
IONX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ACB CONSOLIDATION
29d in phase · OBV DISTRIBUTION
Current IV 30.2%
IV Percentile 6th %ile
Put/Call OI Skew 0.18x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact ACB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
IONX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 181.8%
IV Percentile 4th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact IONX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ACB Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $324.8M market capitalization and -13.8% operating margin.
OpEx & R&D Reinvestment 58.0% of Rev ($182M)
90D Engineering Disclosures 0 Published
IONX Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ACB vs IONX Key Questions & Quantitative Answers

As of Nov 16, 2026, Aurora Cannabis Inc. Common Shares (ACB) is the stronger overall head-to-head candidate over Defiance Daily Target 2X Long IONQ ETF (IONX) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ACB carries a Unified Composite Score of 40.1/100 (SELL) at $4.61 (109.9x Forward P/E, -13.8% operating margin), whereas IONX carries 48.8/100 (HOLD) at $8.27 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While IONX currently prints a higher short-term Unified Composite Score (48.8/100 HOLD vs. ACB 40.1/100 SELL), ACB captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (-13.8% vs. N/A operating margin) and revenue trajectory (-8.8% vs. N/A YoY). Technical & Structure Timing Caution: ACB trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.1); meanwhile IONX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ACB leads the Growth & Scale pillar: ACB posts -8.8% YoY revenue growth and -94.7% YoY earnings growth on $314M TTM revenue (44.2% gross margin, -13.8% operating margin), compared with IONX at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, ACB generates $314M in USD-normalized revenue versus N/A for IONX. In operating R&D and SG&A reinvestment, ACB deploys 58.0% of Rev ($182M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for IONX.

ACB screens cheaper on headline valuation multiples. ACB trades at 109.9x Forward P/E, 109.9x Trailing P/E, N/M PEG, and 0.9x EV/Revenue (-8.1% FCF margin), whereas IONX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ACB (-9.4% ROE) versus IONX (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, ACB carries 30.2% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.18x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.07β · 87% Vol realized risk). By comparison, IONX carries 181.8% implied volatility (4th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (6.79β · 232% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.